On March 16, 2021, Solid Biosciences joined PPMD for a webinar to provide a safety and efficacy update on the ongoing IGNITE DMD phase I/II clinical study of SGT-001 microdystrophin gene therapy in patients with Duchenne muscular dystrophy. 5 years ago Research & Clinical Trial Webinars,Webinars You may also like 1:04:54 Webinar: Advocating for A Successful School Year (September 2024) 2 years ago Care Webinars,Webinars 1:01:24 Webinar: PPMD Advocacy – Raising Our Voices in 2024 and Beyond [Sep 2024] 2 years ago Webinars 1:00:59 Webinar: Advancing DYNE-251 – An Investigational Medicine for Duchenne to Deliver for Patients 2 years ago Research & Clinical Trial Webinars,Webinars dyne therapeutics,DYNE-251 1:05:32 Webinar: Edgewise Therapeutics – Clinical Trials in Becker Muscular Dystrophy 2 years ago Research & Clinical Trial Webinars,Webinars edgewise 58:10 Webinar: Community Progress in Duchenne Newborn Screening 2 years ago Webinars feature,newborn screening 1:01:30 Webinar: Community Update with ITF Therapeutics – Introducing DUVYZAT™ (givinostat) 2 years ago Research & Clinical Trial Webinars,Webinars duvyzat,feature,givinostat,itf therapeutics 45:03 Webinar: Sarepta Therapeutics – Data update from MOMENTUM study, SRP-5051 2 years ago Research & Clinical Trial Webinars,Webinars sarepta 39:33 Webinar: NS Pharma – Overview of New Exon Skipping Trials: Brogidirsen and NS-050/NCNP-03 2 years ago Research & Clinical Trial Webinars,Webinars ns pharma «1…34567…28»Page 5 of 28